Introduction
Inappropriate antimicrobial use in hospitalized patients is associated with prolonged length of stay, increased mortality rate, increased healthcare costs and emergence of antimicrobial resistance. [1] [2] [3] Antimicrobial stewardship programmes (ASPs) are used to improve the quality of antimicrobial therapy, minimize antimicrobial resistance and optimize clinical outcomes. 4 Owing to the extensive use of carbapenems in our ICU, we noticed a new strain of Pseudomonas aeruginosa that was susceptible to many antipseudomonals and resistant to imipenem and meropenem. In September 2016 our intensivists became aware about this issue, and they started to decrease their prescribing of carbapenems. At the beginning of October 2016 the director of our ICU implemented an ASP that officially restricted the use of carbapenems.
Many hospitals have reported better changes in bacterial susceptibilities to carbapenems after implementing ASPs that restricted carbapenem use. [5] [6] [7] However, in these hospitals, other interventions have been implemented, e.g. removal of ceftazidime and cefotaxime from the formulary. So, it is not known if the results can be related solely to the restriction of carbapenems. In this study we compared the antimicrobial susceptibility pattern of P. aeruginosa before and after carbapenem restriction. No additional antimicrobial stewardship interventions were implemented during the second phase.
Methods

Study design
We conducted a two-phase retrospective study. The duration of each phase was 3 months. The first phase was from May until July 2016 (before V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com. carbapenem restriction), whereas the second phase was from September until November 2016 (while implementing carbapenem restriction).
Study location
The study was conducted in the adult ICU at King Saud Medical City (KSMC). KSMC is a public hospital in Riyadh, Saudi Arabia. It is a tertiary care centre for medicine and surgery particularly spinal and neurosurgery. It has 1200 ward beds and 150 ICU beds.
ASP
A carbapenem restriction programme restricted the use of imipenem and meropenem except in three cases: culture-based carbapenem therapy (for ESBL-producing Gram-negative bacteria); empirically after failure of treatment with other antibiotics; and if an infectious disease consultant prescribed carbapenems. The duration of carbapenems therapy was limited to 7 days in most cases. Our ICU has dedicated critical care clinical pharmacists; they made sure that the critical care physicians were following the carbapenem restriction protocol.
Microbiology
The computerized database of the hospital's microbiology laboratory was screened to identify all cultures obtained from patients in the ICU during August and December 2016 (the month before carbapenem restriction and the fourth month after implementing carbapenem restriction). Only cultures that were sent 48 h after ICU admission were considered in calculating the proportion of resistant isolates. Duplicate isolates of P. aeruginosa were removed as follows: same patient, within 3 days of the date of the previous culture, irrespective of antimicrobial susceptibility profile. The antimicrobial susceptibility profile was confirmed by broth dilution method according to CLSI recommendations. 8, 9 Our laboratory reported the susceptibility of P. aeruginosa to eight antibiotics: amikacin, ceftazidime, ciprofloxacin, gentamicin, piperacillin/tazobactam, imipenem, meropenem and cefepime. Susceptibility to colistin was mainly determined and reported if the P. aeruginosa isolate was found to be MDR. P. aeruginosa was considered to be an MDR microorganism if the isolate was resistant to more than two classes of antibiotics. The measure of resistant P. aeruginosa was the proportion of resistant isolates (percentage resistant).
Assessment of antimicrobial consumption
Consumption of antibiotics was obtained from the pharmacy records. The measure of antibacterial consumption was DDDs/1000 patient days in accordance with the WHO recommendation. 10 
Statistical analysis
Consumption of antibiotics was summarized by means and standard deviations. It was compared by Student's t-test while Fisher's exact test was used to compare categorical variables. All comparisons were unpaired and all tests of significance were two tailed. P , 0.05 was considered statistically significant. Microsoft Excel 2010 (Microsoft Corporation, Redmond, WA, USA) was used for data entry. SPSS 20.0 (IBM Corp., Armonk, NY, USA) was used for the statistical analysis of the data. The Institutional Review Board at King Saud Medical City approved this study (IRB number H-01-R-053).
Results
Consumption of some antibiotics changed after implementing carbapenem restriction (Table S1 , available as Supplementary data at JAC Online). The overall carbapenem consumption decreased significantly in the second phase, from 28.44 to 11.67 DDDs/1000 patient days (P " 0.012). There was an increase in ciprofloxacin consumption in the second phase; however, it was not statistically significant (P " 0.190). Interestingly, there was a significant decrease in piperacillin/tazobactam consumption, from 16.46 to 5.89 DDDs/1000 patient days (P " 0.044). The number of cultures that were sent in August and December 2016 is summarized in Table S2 . The overall proportion of P. aeruginosa isolates did not change significantly over time; it changed from 42 of 318 (13.2%) in August to 24 of 205 (11.7%) in December (P " 0.686). However, the proportion of MDR P. aeruginosa was significantly decreased from 15 of 42 (35.7%) in August to only 3 of 24 (12.5%) in December (P " 0.049). After the restriction of carbapenems, the resistance of P. aeruginosa to imipenem and meropenem decreased significantly from 76.0% to 38.5% (P " 0.019) and from 74.1% to 30.0% (P " 0.012), respectively. Susceptibility of P. aeruginosa to other antibacterials was not affected by carbapenem restriction (Table S3) .
The positive cultures for P. aeruginosa were obtained from a variety of clinical specimens including sputum and other respiratory sites, wound, pleural fluid, blood and urine (Table 1) .
Discussion
Rates of carbapenem-resistant P. aeruginosa are increasing. 11, 12 Aggressive prevention strategies, including instituting ASPs, are essential for combating antimicrobial resistance. Bantar et al. 13 created a systematic programme executed by a multidisciplinary team to optimize hospital antibacterial use and demonstrated a statistically significant decrease in carbapenem use over a 2 year period (from 13.5 to 6.2 DDDs/1000 patient days; P " 0.03). This was associated with a significant decrease in the proportion of imipenem-resistant P. aeruginosa isolates, from 19% to 0% (P " 0.02). Pakyz et al. 7 evaluated the relationship between carbapenem restriction and the volume of carbapenem use and both the incidence rate and proportion of carbapenem-resistant P. aeruginosa isolates over a 5 year period in a retrospective, longitudinal, multicentre analysis among a consortium of academic health centres. Hospitals that restricted carbapenems used significantly fewer carbapenems (P " 0.04) and reported lower incidence rates of carbapenem-resistant P. aeruginosa (P " 0.01) for all study years. In this study they did not attempt to measure the consumption of most antipseudomonals except ciprofloxacin. In addition, they did not measure hospital infection control measures. It is possible that hospitals that restricted carbapenems also had more stringent infection control practices, leading to lower incidence Abdallah et al.
rates of carbapenem resistance. In our study no further ASPs were implemented, and the hospital infection control measures were consistent before and after carbapenem restriction; there were no additional ongoing infection control efforts during the second phase. It is worth mentioning that in January 2017 the infection control department changed some elements in its practice. The infection control department started to use quaternary ammonium compound-based disinfectants instead of hydrogen peroxide. In addition, the type of central line dressing was changed. The present study examined the impact of carbapenem restriction on the antibiotic susceptibility pattern of P. aeruginosa isolates in the adult ICU. While important, confirmation of the isolates as infectious was beyond the scope of this study. Similar to other studies, 7, 13 we observed that after carbapenem restriction, there was a statistically significant decrease in the proportion of carbapenem-resistant P. aeruginosa isolates. Although some investigators 14, 15 argued that a long period of time is required for a change in antibiotic prescribing practice to show an effect on the antimicrobial susceptibility pattern, the present study proved that even a short duration of change in antibiotic prescribing habits might cause a change in the antimicrobial susceptibility pattern.
There are limitations to this study. First, carbapenem resistance in P. aeruginosa is more complex than simply carbapenem use; many additional risk factors have been reported from other investigations. [16] [17] [18] Many of these carbapenem-resistant isolates are likely to be MDR, and the use of other antibiotics has been found to select for carbapenem resistance. 19 In addition, prolonged antibiotic treatment is a risk factor for the emergence of drug-resistant P. aeruginosa. 20 Second, we did not investigate the clinical outcomes (e.g. length of stay, ventilator days, mortality rate) before and after carbapenem restriction. Third, antipseudomonals' susceptibility data were missing in some culture reports. Finally, there was a significant unexpected decrease in piperacillin/tazobactam consumption in the second phase of this study, which might be considered a potential confounder for our results. The decrease in piperacillin/tazobactam consumption was accompanied by an increase in ciprofloxacin consumption, but the increase in ciprofloxacin consumption was not statistically significant.
Conclusions
These data suggest that restricting carbapenems, even for a short duration, may be an effective strategy for managing the problem of carbapenem resistance in P. aeruginosa. There are few antibacterial agents under development for MDR microorganisms, particularly Gram-negative bacteria, and preserving the effectiveness of available antibacterials is a necessary strategy in the management of antibacterial resistance.
